


**Product Name** : Lenalidomide  
**Cat. No.** : PC-20467  
**CAS No.** : 191732-72-6  
**Molecular Formula** : C<sub>13</sub>H<sub>13</sub>N<sub>3</sub>O<sub>3</sub>  
**Molecular Weight** : 259.27  
**Target** : E3 Ligase Ligand  
**Solubility** : 10 mM in DMSO



## Biological Activity

Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue for PROTAC design, Lenalidomide is a ligand of ubiquitin E3 ligase cereblon (CRBN), and causes selective ubiquitination and degradation of IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase.

Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.

Lenalidomide (CC-5013) inhibits production of pro inflammatory cytokines TNF- $\alpha$ , IL-1, IL-6, IL-12 and elevates the production of anti-inflammatory cytokine IL-10 from human PBMCs.

Lenalidomide (CC-5013) downregulates the production of IL-6 directly and also by inhibiting multiple myeloma (MM) cells and bone marrow stromal cells (BMSC) interaction.

Orally administered lenalidomide (250 mg/kg per day) reduces vascularization and total microvascular length in a rat mesenteric window assay.

## References

Krönke J, et al. Oncoimmunology. 2014 Jul 3;3(7):e941742.

Kotla V, et al. J Hematol Oncol. 2009 Aug 12;2:36.

Lopez-Girona A, et al. Leukemia. 2012 Nov;26(11):2326-35.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com